Ani Pharmaceuticals, Inc. · NASDAQ:ANIP

Ani Pharmaceuticals — Jefferies Healthcare Conference June 2023

15 slides from Ani Pharmaceuticals's conference presentation, Jun 9, 2023

  1. Slide 1: Jefferies Healthcare Conference June 2023

    © 2023 ANI Pharmaceuticals, Inc. 1 © 2023 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2023

  2. Slide 2: Disclaimer

    © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward - looking statements, including informatio n about management's view of the Company’s future expectations, plans and prospects, as well as other forward - looking sta

  3. Slide 3: ANI Is Well Positioned to Drive Sustainable Profitable Growth

    © 2023 ANI Pharmaceuticals, Inc. 3 ANI Pharmaceuticals Is Well Positioned to Drive Sustainable Profitable Growth Scaling up Rare Disease business with Purified Cortrophin Gel (PCG) launch momentum and adding assets that leverage our Rare Disease infrastructure Maximize value from Established Brands

  4. Slide 4: 2022 Was a Landmark Year for ANI

    © 2023 ANI Pharmaceuticals, Inc. 4 2022 Was a Landmark Year for ANI, Which We Believe Creates Strong Growth Momentum for 2023 and Beyond Revenues ($ million) Adjusted Non - GAAP EBITDA (1) ($ million) (1) Adjusted non - GAAP EBITDA is a non - GAAP financial measure. For reconciliation of Adjusted No

  5. Slide 5: Record Quarterly Revenues and Adjusted Non-GAAP EBITDA in First Quarter 2023

    © 2023 ANI Pharmaceuticals, Inc. 5 ANI Achieved Record Quarterly Revenues and Adjusted Non - GAAP EBITDA in First Quarter of 2023 Revenues ($ million) Adjusted Non - GAAP EBITDA (1) ($ million) $42 (1) Adjusted non - GAAP EBITDA is a non - GAAP financial measure. For reconciliation of Adjusted Non -

  6. Slide 6: Strong Launch Momentum for Purified Cortrophin Gel

    © 2023 ANI Pharmaceuticals, Inc. 6 Strong Launch Momentum for Foundational Rare Disease Asset, Purified Cortrophin Gel Accelerating momentum with record quarterly number of new cases initiated in Q1’23 and record monthly new patient starts and cases initiated in April’23 • Continued growth in number

  7. Slide 7: ACTH Class Has Shown Year-over-Year Unit Growth Since PCG Launch

    © 2023 ANI Pharmaceuticals, Inc. 7 Importantly, ACTH Class Has Shown Year - over - Year Unit Growth Since PCG Launch and for the First Time Since 2019 Source: IQVIA ACTH Units – Year - over - Year Change From June 2022 to April 2023, the ACTH category has demonstrated eleven months of consecutive ye

  8. Slide 8: Focused Efforts to Strengthen Generics Business

    © 2023 ANI Pharmaceuticals, Inc. 8 Focused Efforts to Strengthen Generics Business, Enhancing Growth Momentum Generics Revenues ($ million) 1 Superior pipeline and new product launch execution Driving cost - excellence Ensuring reliability of supply • Increased R&D investment with focus on niche opp

  9. Slide 9: Entirely U.S. Based Manufacturing Footprint; Strong GMP Track Record

    © 2023 ANI Pharmaceuticals, Inc. 9 Entirely U.S. Based Manufacturing Footprint; Strong GMP Track Record, Including Successful Recent Audits at All Three Sites • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space • Lab space - R&D/analytical testing • Solutions, suspensions, t

  10. Slide 10: Executive Leadership Team with Proven Track Records

    © 2023 ANI Pharmaceuticals, Inc. 10 Executive Leadership Team with Proven Track Records and Broad Industry Expertise ‒ 20+ years of legal and leadership experience in specialty and generics pharmaceuticals ‒ Served as Vice President and Associate GC for Amneal Pharmaceuticals ‒ Previously with Morga

  11. Slide 11: ANI Is Well Positioned to Drive Sustainable Profitable Growth

    © 2023 ANI Pharmaceuticals, Inc. 11 ANI Pharmaceuticals Is Well Positioned to Drive Sustainable Profitable Growth Scaling up Rare Disease business with Purified Cortrophin Gel (PCG) launch momentum and adding assets that leverage our Rare Disease infrastructure Maximize value from Established Brands

  12. Slide 12: Jefferies Healthcare Conference June 2023

    © 2023 ANI Pharmaceuticals, Inc. 12 © 2023 ANI Pharmaceuticals, Inc. 12 Jefferies Healthcare Conference June 2023

  13. Slide 13: EBITDA Reconciliation – 1Q 2023 and 2022

    © 2023 ANI Pharmaceuticals, Inc. 13 EBITDA Reconciliation – 1Q 2023 and 2022 2023 2022 Net Loss 1,439$ (20,130)$ Add/(Subtract): Interest expense, net 7,696 6,613 Other expense, net 34 89 Income tax provision (benefit) 726 (5,767) Depreciation and amortization 14,700 14,557 Contingent consideration

  14. Slide 14: EBITDA Reconciliation – Full Year 2022 and 2021

    © 2023 ANI Pharmaceuticals, Inc. 14 EBITDA Reconciliation – Full Year 2022 and 2021 (1) Adjustment to other expense, net excludes $750K of income related to the sale of an ANDA during the three months ended December 31, 2021, and excludes $750K and $1.9 million of income related to the sale of an AN

  15. Slide 15: ANI's Business Development Engine Fueled Growth in Earlier Years

    © 2023 ANI Pharmaceuticals, Inc. 15 ANI’s Strong Business Development Engine Fueled Growth in Earlier Years Brands Class Seller Products 2021 Sandoz Veregen Oxistat Apexicon Pandel 2018 AZ Atacand & Atacand HCT Casodex & Arimidex 2017 Cranford Inderal XL Innopran XL 2016 Akrimax Inderal LA/Prop ER 2

ANI Pharmaceuticals — Jefferies Healthcare Conference June 2023 on 6ix